Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Depreciation & Amortization (CF): 2019-2025

Historic Depreciation & Amortization (CF) for BridgeBio Pharma (BBIO) over the last 5 years, with Sep 2025 value amounting to $1.4 million.

  • BridgeBio Pharma's Depreciation & Amortization (CF) fell 9.10% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year decrease of 14.73%. This contributed to the annual value of $6.1 million for FY2024, which is 6.45% down from last year.
  • As of Q3 2025, BridgeBio Pharma's Depreciation & Amortization (CF) stood at $1.4 million, which was up 6.15% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Depreciation & Amortization (CF) peaked at $3.5 million during Q2 2021, and registered a low of $265,000 during Q3 2021.
  • In the last 3 years, BridgeBio Pharma's Depreciation & Amortization (CF) had a median value of $1.6 million in 2024 and averaged $1.5 million.
  • Data for BridgeBio Pharma's Depreciation & Amortization (CF) shows a peak YoY increase of 520.75% (in 2022) and a maximum YoY decrease of 54.62% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Depreciation & Amortization (CF) stood at $1.5 million in 2021, then grew by 8.78% to $1.7 million in 2022, then decreased by 4.52% to $1.6 million in 2023, then declined by 13.75% to $1.4 million in 2024, then declined by 9.10% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $1.3 million for Q2 2025, and $1.3 million during Q1 2025.